Table 1.
Baseline characteristics of 2955 patients after pancreatoduodenectomy for pancreatic cancer
| All patients (n = 2955) | |
|---|---|
| Age, median years (IQR) | 68.0 (61.0–74.0) |
| Missing | 0 |
| Female | 1372 (46.7%) |
| Missing | 0 |
| ASA classification | |
| 1–2 | 950 (69.7%) |
| 3–4 | 413 (30.3%) |
| Missing | 119 |
| CCIa | |
| 0 | 602 (47.1%) |
| 1 | 466 (36.4%) |
| 2 | 156 (12.2%) |
| 2 | 57 (4.4%) |
| Missing | 205 |
| Chemo(radio)therapy | |
| None | 1273 (43.3%) |
| Neoadjuvant | 96 (3.3%) |
| Adjuvant | 1454 (49.5%) |
| Both | 115 (3.9%) |
| Missing | 0 |
| Minimally invasivea,b | 141 (9.7%) |
| Missing | 28 |
| PD performed in center with volume ≥ 40 PD/year | 1361 (46.5%) |
| Missing | 0 |
| Tumor diameter in mmc, median (IQR) | 30.0 (23.0–39.0) |
| Missing | 199 |
| T staged | |
| 1 | 304 (10.3%) |
| 2 | 1799 (61.2%) |
| 3 | 689 (23.4%) |
| 4 | 149 (5.1%) |
| Missing | 14 |
| Lymph nodes evaluated (IQR) | 14.0 (9.0–12.0) |
| Missing | 24 |
| Lymph nodes positive (IQR) | 2.0 (0.0–4.0) |
| Missing | 21 |
| LNR, median (IQR) | 0.1 (0.0-0.3) |
| Missing | 46 |
| Year of resection | |
| 2009–2011 | 624 (21.1%) |
| 2012–2013 | 573 (19.5%) |
| 2014–2015 | 549 (18.7%) |
| 2016–2017 | 604 (20.6%) |
| 2018–2019 | 588 (20.1%) |
| Missing | 0 |
Numbers are depicted as numbers with valid percentages, unless indicated otherwise. ASA American Society of Anesthesiologists, CCI Carlson Comorbidity Index, PD pancreatoduodenectomy, LNR lymph node ratio, SD standard deviation, IQR interquartile range
aOnly in patients between 2015 and 2019 (n = 1482)
bincluding patients with conversion to open surgery (n = 34)
cbased on PALGA reports
dif pT stage was unavailable, cT stage was used